PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
08 nov. 2021 05h15 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech first quarter 2021 interim results
07 mai 2021 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation. ...
OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies
05 mai 2021 05h00 HE
|
PCI Biotech Holding ASA
Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused...
PCI Biotech fourth quarter and preliminary full year 2020 results
24 févr. 2021 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 24 February 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full year 2020 results. Please find enclosed the...
PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
10 févr. 2021 02h31 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released...
PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
26 mars 2020 04h12 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a...
PCI Biotech's fourth quarter and preliminary 2019 results
26 févr. 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...